Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial
Authors:
Top Cited Papers
Open Access
- 21 February 2022
- journal article
- research article
- Published by Springer Nature in Critical Care
- Vol. 26 (1) , 1-14
Abstract
Background: Severe acute respiratory syndrome coronavirus-2 (SARS–CoV-2)-induced acute respiratory distress syndrome (ARDS) causes high mortality. Umbilical cord-derived mesenchymal stromal cells (UC-MSCs) have potentially relevant immune-modulatory properties, whose place in ARDS treatment is not established. This phase 2b trial was undertaken to assess the efficacy of UC-MSCs in patients with SARS–CoV-2-induced ARDS. Methods: This multicentre, double-blind, randomized, placebo-controlled trial (STROMA–CoV-2) recruited adults (≥ 18 years) with SARS–CoV-2-induced early (< 96 h) mild-to-severe ARDS in 10 French centres. Patients were randomly assigned to receive three intravenous infusions of 106 UC-MSCs/kg or placebo (0.9% NaCl) over 5 days after recruitment. For the modified intention-to-treat population, the primary endpoint was the partial pressure of oxygen to fractional inspired oxygen (PaO2/FiO2)-ratio change between baseline (day (D) 0) and D7. Results: Among the 107 patients screened for eligibility from April 6, 2020, to October 29, 2020, 45 were enrolled, randomized and analyzed. PaO2/FiO2 changes between D0 and D7 did not differ significantly between the UC-MSCs and placebo groups (medians [IQR] 54.3 [− 15.5 to 93.3] vs 25.3 [− 33.3 to 104.6], respectively; ANCOVA estimated treatment effect 7.4, 95% CI − 44.7 to 59.7; P = 0.77). Six (28.6%) of the 21 UC-MSCs recipients and six of 24 (25%) placebo-group patients experienced serious adverse events, none of which were related to UC-MSCs treatment. Conclusions: D0-to-D7 PaO2/FiO2 changes for intravenous UC-MSCs-versus placebo-treated adults with SARS–CoV-2-induced ARDS did not differ significantly. Repeated UC-MSCs infusions were not associated with any serious adverse events during treatment or thereafter (until D28). Larger trials enrolling patients earlier during the course of their ARDS are needed to further assess UC-MSCs efficacy in this context. Trial registration: NCT04333368. Registered 01 April 2020, https://clinicaltrials.gov/ct2/history/NCT04333368.Keywords
Funding Information
- Agence Nationale de la Recherche (ANR20COVI0016)
- Direction Générale de l’offre de Soins (COVID-19-20-0004)
This publication has 48 references indexed in Scilit:
- Differential Cytotoxicity of Corticosteroids on Human Mesenchymal Stem CellsClinical Orthopaedics and Related Research, 2015
- Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trialThe Lancet Respiratory Medicine, 2015
- Protein synthesis and secretion in human mesenchymal cells derived from bone marrow, adipose tissue and Wharton’s jellyStem Cell Research & Therapy, 2014
- Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot studyRespiratory Research, 2014
- Mesenchymal stem cells: immune evasive, not immune privilegedNature Biotechnology, 2014
- The Size of Mesenchymal Stem Cells is a Significant Cause of Vascular Obstructions and StrokeStem Cell Reviews and Reports, 2014
- When Is a Negative Phase II Trial Truly Negative?American Journal of Respiratory and Critical Care Medicine, 2008
- Clinical relevance of the PaO2/FiO2 ratioCritical Care, 2008
- Variation in the PaO2/FiO2 ratio with FiO2: mathematical and experimental description, and clinical relevanceCritical Care, 2007
- Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2000